TPS1104 Background: Treatment for mTNBC is limited, with chemotherapy the mainstay
(bevacizumab is approved in> 80 countries). Atezolizumab (atezo; MPDL3280A), a …

Background: The management of mTNBC is a therapeutic challenge, and chemotherapy
remains the mainstay of treatment. Atezolizumab (atezo; MPDL3280A) is a humanized anti …

Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poor
prognosis, and chemotherapy remains the mainstay of treatment. Cancer immunotherapy …

1009 Background: Atezolizumab (atezo; MPDL3280A) is a humanized MAb that inhibits
binding of PD-L1 to PD-1 and B7. 1, thus restoring tumor-specific T-cell immunity. Atezo has …

Importance The humanized monoclonal antibody atezolizumab targets programmed death-
ligand 1 and has demonstrated durable single-agent activity in a subset of metastatic triple …

The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for
PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining …

Importance Agents targeting programmed death ligand 1 (PD-L1) have demonstrated
efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are …

Introduction Triple-negative breast cancer (TNBC) accounts for approximately 10%-15% of
all diagnosed breast cancers and is associated with an aggressive natural history and poor …

1067 Background: In the IMpassion130 study in 1L mTNBC (N= 902), PFS with atezo+ nP
was significantly better than with placebo (P)+ nP in ITT (HR, 0.80) and PD-L1 IC+ (HR …

1015 Background: Atezolizumab (anti-PD-L1) plus nab-paclitaxel was shown to improve
outcomes in mTBNC in a phase III clinical trial. Subjects were required to be> 12 months …